Bisphosphonates are commonly used in patients with breast cancer to reduce skeletal-related events in metastatic disease,mitigate bone loss,and increase bone mineral density.Bisphosphonates can decrease and cleare disseminated tumor cells in bone marrow and circulation tumor cells and then prevent breast cancer relapse and metastases.Bisphosphonates can lighten tumor burden in the breast when administered with neoadjuvant chemotherapy,and improve pathology complete remission rates.Inconsistence is observed in large trials using bisphosphonates in the adjuvant setting of early breast cancer,but survival improvement is mostly seen in postmenopausal patients with low levels of estrogens.

In recent years,mTOR inhibitors such as temsirolimus and everolimus are considered to be effective as a new generation of anti-tumor agent.Their efficacies are proven by a number of clinical trials especially in the field of overcoming the drug resistance of tumor cells.But the optimal combination regimen of the mTOR inhibitors and other anti-tumor drugs is still to be validated.

Chemotherapy with or without molecule-targeting agents is the primary choice for patients with unresectable metastatic coloreetal cancer. New treatment strategies like intermittent therapy and maintenance therapy may not inferior to treatment until progression or unacceptable toxicity in maintaining the benefit for patients who responded or had stable disease after the first-line therapy,and also can reduce the drug related side effeets and improve the quality of life.

CENP-Fisacell-cycledependentkinetochoreprotein,whoseexpressionandlocalization patterns are regulated in a cell cycle-dependent manner.CENP-F plays an important role in the development and progress of malignant tumor.The expression of CENP-F is up-regulated in many tumors.It serves as an important marker in cell proliferation.Studies have demonstrated that CENP-F is involved in tumor genesis, progress,invasiveness,relapse and prognosis.CENP-F might be a valuable prognostic marker and potential therapy target in cancer treatment.

Medical therapy is the primary choice for patients with advanced biliary tract cancer.Gemcitabine has been proved to be one of the most effective drugs and a standard regimen has been made when combined with cisplatin.Studies of the second line therapy is few.Targeted therapy has a potential to create a new era in the future but needs to be validated in large clinical trials.

This paper analyzes the present situation of intellectualization of hospital outpatient service building,points out its characteristics and disposition requirement,and proposes the design of intellectualized outpatient service.After rectifying outpatient procedure,our hospital designs and practices the new one,which provides humanism service for outpatient.

With the development of phamacogenomic and molecular biology, it has been revealed that the curative effect of non-small-cell lung cancer (NSCLC) is closely related to tumor molecular markers. Predictive biomarkers in NSCLC patients, including ERCC1, BRCA1, hMLH1, hMSH2, RRM1, β-tubulin, TS,EGFR and K-ras, can predict individual patient's response to chemotherapy or targeted therapy, making individualized therapy be possible.

Poly ADP-Ribose Polymerase(PARP)plays an important role in the detection and repair of DNA damage.Inhibition of the PARP activity in the homologous-recombination defective cancer cell could lead to genomic instability and ultimately cause cell death.In preclinical study PARP inhibitors have demonstrated the capacity of enhancing sensitivity of cancel cells to chemotherapy agents and radiation.PARP inhibitors also showed antitumour potential in early clinical trials as monotherapy or combined with chemotherapy.

Anthracycline-based chemotherapeutic agents were extensively applied to the treatment of breast cancer. The relation of its response to TOP2A gene was proved by a number of clinical studies demonstrating that patients with both HER2 gene amplification and TOP2A gene aberration have a favored outcome,but a consensus was not yet achieved.

Objective To evaluate the association between B-cell non-Hodgkin lymphoma (NHL) and hepatitis B virus (HBV).Methods The positive rates of HBV markers in 284 patients of B-cell NHL who were admitted to our department between January 2003 and December 2009 were investigated.The positive rates of HBV markers in colorectal cancer patients were used as controls.Results The HBsAg-positive rates of patients aged 18～ 39 and stage m/Ⅳ patients were 42.6 ％ (26/61) and 37.0 ％ (50/135),which was higher than other groups.The x2 value and P value were 7.573 and 6.874,0.023 and 0.009,respectively.Compared with the control group, the B-cell NHL had significantly higher prevalence of positive HBsAg and positive HBeAg (29.6 ％ vs 14.5 ％,6.7 ％ vs 0.8 ％ ).The Wald values were 25.174 and 20.496,respectively.Both of the P value were ＜0.001 and lower prevalence of positive anti-HBs (45.4 ％ vs 58.0 ％,Wald =11.062,P =0.001).The coexpression of HBsAg, HBeAg and anti-HBc was higher in the B-NHL group than in the control group (6.0 ％ vs 0.8 ％,x2 =31.619,P ＜0.001).Similarly,the coexpression of HBsAg,anti-HBe,and anti-HBc was higher in the B-NHL group (16.2 ％ vs 11.5 ％,x2 =4.542,P =0.033).Significantly higher rate of positive anti-HBc and negative anti-HBs was observed in the B-NHL group (37.0 ％ vs 24.5 ％,Wald =17.708,P ＜ 0.001),whereas the same group showed a lower rate of negative anti-HBs compared with the control group (20.8 ％ vs 27.8 ％, Wald =5.646, P =0.017).Conclusion This finding of a positive association between HBV infection and B-NHL suggests that HBV may play an etiologic role in the induction of B-NHL.